Wuxi

Researchers are evaluating the safety and effectiveness of Ivonescimab, a PD-1/VEGF bispecific antibody, combined with docetaxel compared to standard treatment in patients with advanced non-small cell lung cancer (NSCLC). These patients have shown long-term benefit from first-line immune checkpoint inhibitors but have detectable circulating tumor DNA minimal residual disease (ctDNA-MRD). This phase II, randomized, open-label, multicenter trial builds on previous findings to develop personalized treatment strategies aiming to delay cancer progression and improve outcomes by integrating molecular monitoring with adaptive therapies. The study involves ctDNA-positive patients receiving escalation treatment with Ivonescimab intravenously at 20 mg/kg on Day 1 every three weeks, combined with docetaxel at 75 mg/m² intravenously on Day 1 every three weeks. Treatment continues until lack of clinical benefit, unacceptable toxicity, completion of 24 months, or other protocol-specified criteria. The control group continues their original immunotherapy maintenance or immunotherapy combined with chemotherapy. Dose and schedule adjustments for chemotherapy may be made based on patient tolerance. Participants will undergo regular visits for treatment, imaging assessments, and laboratory tests to monitor safety and effectiveness, including progression-free survival over three years in the ctDNA-positive population. Eligibility includes adults aged 18 to 75 with advanced NSCLC meeting specific health and laboratory criteria. Safety monitoring includes tracking adverse effects, imaging for tumor status, and laboratory evaluations. Participants remain in the study until treatment discontinuation or study completion, with close follow-up throughout.

Nasopharyngeal carcinoma (NPC) is commonly found in regions like southern China, northern Africa, and Alaska, with a high incidence in Guangdong Province. Early-stage NPC patients tend to have better outcomes after receiving combined radiotherapy and chemotherapy compared to those with advanced disease. Researchers are exploring the use of artificial intelligence to improve early detection of NPC during nasoendoscopic examinations using white light imaging (WLI) and narrow-band imaging (NBI). This study aims to develop and validate a novel computer-aided diagnostic system for identifying various nasopharyngeal lesions. The study uses rigid nasal endoscopes inserted through the nasal passage to carefully examine different parts of the nasopharynx, including the posterior nostril, walls of the nasopharynx, torus tubarius, auditory tube opening, and Rosenmüller recess. During the procedure, imaging is done first with conventional WLI and then switched to NBI to capture representative images. Any lesions detected by either imaging technique will be biopsied for further analysis. This approach helps gather detailed information to support the intelligent diagnostic system development. Participants will undergo nasoendoscopic examinations where images are collected and preserved for analysis. Researchers will confirm pathological diagnoses at baseline to evaluate the system's accuracy. The study involves adults aged 18 years and older and includes monitoring for any contraindications such as coagulation issues or allergies. The data collected will contribute to understanding the system's role in detecting nasopharyngeal carcinoma and potentially improving early diagnosis and treatment outcomes.